Summary of Montage (688008.SS) Conference Call Company Overview - **Company**: Montage (688008.SS) - **Industry**: Memory Interface Integrated Circuits (ICs) Key Financial Results - **4Q25 Operating Income**: Rmb545 million, representing a **68% QoQ** and **77% YoY** increase, which was **11% higher than Goldman Sachs estimates (GSe)** attributed to the reversal of stock-based compensation expenses [1] - **Revenue**: Rmb1.4 billion, a **31% YoY** increase but a **2% QoQ** decrease, aligning with pre-announcement expectations [1] - **Gross Margin**: 64.5%, consistent with previous announcements and showing improvement from **63.3% in 3Q25** and **58.2% in 4Q24** [1] - **R&D Expenses**: Increased by **81% YoY**, indicating a strong commitment to product development [1] - **Marketing Expenses**: Increased by **43% YoY** [1] R&D and Product Development - **R&D Focus**: Montage is expanding its product pipeline from RCD/RDB memory interface ICs to MRDIMM, CKD, and PCIe Retimer in the short term, and PCIe Switch/CXL controller in the medium to long term [2] - **Key R&D Progress**: - Mass production of DDR5 Gen4 RCD initiated - Completed R&D for DDR5 Gen5 RCD, Gen 2 MRCD/MDB, and CKD chip - Advancements in PCIe interface ICs, including PCIe 6.x/CXL 3.x Retimer and ongoing development of PCIe 7.0 Retimer and PCIe switch [8] Financial Projections - **Revenue Growth Forecast**: Expected to reach Rmb5.5 billion in 2025, Rmb8.7 billion in 2026, and Rmb11.3 billion in 2027 [12] - **Net Income Projections**: Anticipated to grow from Rmb2.2 billion in 2025 to Rmb5.0 billion in 2027 [12] - **EPS Growth**: Projected to increase from Rmb1.95 in 2025 to Rmb4.11 in 2027 [12] Valuation and Price Target - **12-Month Price Target**: Rmb227.00 for A-shares and HK$268.00 for H-shares, indicating an upside of **72%** and **62.3%** respectively [27] - **Valuation Methodology**: Based on a 31x 2030E discounted P/E for A-shares and a 33x 2030E P/E for H-shares [25] Risks and Challenges - **Key Risks**: - Weaker-than-expected growth in the memory interface IC market - Slower-than-expected new product introductions - Increased market competition [26] Conclusion Montage is positioned for growth with significant investments in R&D and a robust product pipeline. The financial results for 4Q25 indicate strong performance, and the company is optimistic about future revenue and profit growth. However, potential risks in market dynamics and competition should be monitored closely.

Investment Rating - The report maintains a "BUY" rating for 3SBio, indicating a potential return of over 15% over the next 12 months [6][15]. Core Insights - 3SBio reported a revenue of RMB 17.7 billion in 2025, a significant increase of 94.3% year-over-year, primarily driven by RMB 9.4 billion in out-licensing income from Pfizer for product 707. However, product sales experienced a decline of 10.3% year-over-year to RMB 8.0 billion due to challenges from China's VBP and reimbursement controls [1][2]. - The company is expected to maintain high R&D investments to accelerate pipeline progress, with a focus on product 707, which is seen as the primary valuation anchor due to Pfizer's aggressive global development strategy [1][6]. - The report anticipates that while commercialized products, especially TPIAO, may face continued pressure in 2026, new product approvals and pipeline candidates could help offset declines in traditional product sales [6][8]. Financial Summary - Revenue projections for 2026 are revised down to RMB 9.17 billion, reflecting a 48.2% decline from 2025, with a net profit forecast of RMB 1.90 billion, down 77.6% year-over-year [2][7]. - The report highlights a significant increase in R&D and administrative expense ratios, which rose approximately 4 percentage points and 2 percentage points, respectively, due to accelerated clinical investments and one-off share-based compensation [1][6]. - The target price for 3SBio has been adjusted to HK$ 34.87 from a previous HK$ 37.43, representing a 54% upside from the current price of HK$ 22.64 [3][6]. Pipeline and Product Development - 3SBio has developed a broad pipeline of 27 candidates, with several already obtaining US FDA INDs, including SSS67 and SSS68, which target various medical conditions and demonstrate the company's global R&D strategy [6][8]. - Near-term catalysts include updated Phase 2 data for NSCLC and EC at ASCO 2026, which are expected to drive milestone payments and enhance earnings [6][8]. - Recent product approvals, such as NuPIAO and SSS20, along with NRDL inclusion for oral paclitaxel, are anticipated to generate revenue in 2026 and partially offset declines from traditional products [6][8].

Core Business Overview - The company estimates that its core business, excluding Jakafi, has the potential to reach sales of approximately $3 billion to $4 billion over the next 5 years [2] - The core business includes FDA-approved marketed products such as Opzelura, Niktimvo, and Monjuvi, which are expected to grow to a size comparable to Jakafi by 2030 [2] - Additional products in the pipeline, including XR and povorcitinib, are anticipated to receive approval within the next 12 months [2] Research and Development Focus - The company has a pipeline of 7 assets, with about 80% of its R&D investment concentrated in the areas of hematology, oncology, and immunology [3]

Financial Data and Key Metrics Changes - Total revenue increased by 8% in 2025, with product revenue growing by 10% driven by global demand for innovative medicines [5][18] - Core EPS grew by 11%, aligning with full-year guidance [19] - Operating profit increased by 9%, with a core gross margin of 82% [18][19] - Cash flow from operating activities rose by 23% to $14.6 billion [20] - Interest-bearing debt is close to $30 billion, with a net debt-to-EBITDA ratio of 1.2 times [21] Business Line Data and Key Metrics Changes - Oncology revenues reached $25.6 billion, up 14% year-on-year, with Tagrisso, Imfinzi, and Enhertu contributing significantly [25][26] - Biopharmaceuticals revenue increased by 5% to $23 billion, with growth medicines outpacing declines from generic competition [38] - Rare Disease revenue grew by 4% to $9.1 billion, driven by neurology indications and global expansion [50] Market Data and Key Metrics Changes - U.S. market saw a 10% growth, while emerging markets outside of China grew by 22% [10] - China experienced a 4% growth despite losing Pulmicort to generics, maintaining its position as the largest pharma company in the region [10] - Europe accounted for 35% of Farxiga's total revenue, with patent protections extending to 2028 [22] Company Strategy and Development Direction - The company aims to reach $80 billion in revenue by 2030, with a focus on R&D investments in innovative technologies and new medicines [12][57] - Plans to strengthen manufacturing and R&D footprints in the U.S. and China to support growth [8] - Emphasis on diversification to mitigate concentration risk and ensure resilience against regional disruptions [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining growth momentum into 2026 despite known headwinds, including patent expirations and market competition [21][22] - The company anticipates a mid- to high-single-digit percentage growth in total revenue for 2026, driven by strong underlying business momentum [21] - Management highlighted the importance of continued investment in R&D to drive long-term growth beyond 2030 [12][57] Other Important Information - The company secured 43 approvals for its medicines across major regions in the last 12 months [6] - A second interim dividend of $2.17 per share was declared, with plans to increase the annual dividend to $3.30 per share in 2026 [21] Q&A Session Summary Question: Growth beyond 2030 and readouts in 2026 - Inquiry about the $10 billion risk-adjusted peak sales potential and the mix of assets contributing to this figure, as well as expectations for higher success rates following strong performance in the previous year [61] Question: Update on China - Request for an update on the 2026 outlook for China, including new launches and profitability compared to historical performance [62]

As the head of the finance department, do you look at all the things in this room and think this costs that amount of money, this costs that amount of money. >> Thankfully, no. I don't I don't when I think about cameras in general and what we, you know, when we first I'll give you a really prime example, the film cameras, when you thought about it, okay, are we building two.Are we building four. Are you building eight. Right.And and that's where I start to think about, well, what what makes the most sense f ...

Core Insights - The UK has experienced a slight downturn in R&D tax relief claims for the tax year 2023 to 2024, with a provisional estimate of £7.6 billion ($10.2 billion), representing a 2% decrease from the previous year [1] - R&D expenditure also fell by 1% to £46.1 billion ($62.03 billion) [1] Summary by Categories R&D Tax Relief Claims - The SME scheme saw a significant 29% reduction in tax relief claims, amounting to £3.15 billion, while the RDEC scheme experienced a 36% increase to £4.41 billion [2] - Overall, the number of R&D tax credit claims decreased by 26% year-on-year to 46,950, with the SME scheme facing a 31% reduction in claims and the RDEC scheme seeing a modest 5% drop [3] Impact on SMEs - There was a notable 45% fall in first-time claims from SMEs, attributed to lower relief rates and more demanding administrative requirements [4] - Concerns have been raised regarding the discouraging effect of recent changes on smaller businesses considering innovation investments [3] Larger Businesses and RDEC - Larger businesses have benefited from an increased share of relief at 47%, although the number of RDEC claims has decreased, but to a lesser extent [4] - The increased RDEC rate has made it more feasible for larger companies to undertake projects with higher financial certainty [5] Future Considerations - There are cautions against further changes that could undermine R&D investment, as recent reforms aimed at reducing error and fraud have had a positive impact [5] - HMRC has earmarked £2.4 billion for tax reliefs and expenditure credits for the creative industries for the fiscal year ending 31 March 2024 [5]

Financial Data and Key Metrics Changes - For Q4, the company recorded net sales of $251 million, up 6% sequentially and up 33% year over year [39][41] - Adjusted gross margin was 53.2%, up 80 basis points sequentially and up 430 basis points year over year [40] - Adjusted operating income was $49.8 million, resulting in an adjusted operating margin of 19.9%, up 160 basis points sequentially and up 1070 basis points year over year [40] - Adjusted diluted earnings per share increased to 40 cents, up from 26 cents in Q3 and up from a loss of 6 cents in Q4 of the previous year [41][42] - Net debt was reduced to $411 million, a decrease of 68% from $1.3 billion at the end of FY 2024 [42][43] Business Line Data and Key Metrics Changes - Infrastructure net sales for Q4 were $69.1 million, up 5% sequentially and up 75% year over year [16] - Data center net sales reached a record $50 million, up 16% sequentially and up 183% year over year [16] - High-end consumer net sales for Q4 were $35.4 million, up 10% year over year, with FY 2025 net sales at $147 million, up 17% year over year [22][25] - Industrial net sales for Q4 were $146.6 million, up 12% sequentially and up 21% year over year, with LoRa-enabled solutions recording Q4 net sales of $37.1 million, up 28% sequentially and up 205% year over year [27][28] Market Data and Key Metrics Changes - The company expects net sales from the infrastructure end market to increase sequentially, with data center applications leading growth [44] - The high-end consumer end market is expected to see slight increases reflective of seasonality, while the industrial end market is anticipated to decline due to seasonality in the IoT portfolio [45] Company Strategy and Development Direction - The company is focused on three core priorities: portfolio optimization and simplification, strategic investment in R&D, and driving margin expansion through operational leverage and AI [11][15] - The company aims to enhance profitability through portfolio optimization and leveraging AI for efficiency [15] - The company is prioritizing divestitures of non-core assets to improve balance sheet strength and operational focus [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the trajectory of the business, citing strong fundamentals and a favorable market environment [65] - The company anticipates continued growth in the data center segment despite temporary headwinds from the Copper Edge portfolio [70] - Management highlighted the importance of customer engagement and innovation in driving future growth [102] Other Important Information - The company achieved a significant milestone with the 5G Redcap certification in collaboration with AT&T and Qualcomm, positioning it for scalable solutions across industries [36] - The company is actively engaged with over 20 potential customers for its CopperEdge portfolio, indicating a strong interest in new applications [58] Q&A Session Summary Question: Can you expand on the Copper Edge portfolio and its future? - Management indicated that revenue for Copper Edge is expected to be below $50 million in FY 2026, with ongoing engagement with over 20 customers for various applications [56][58] Question: What is the outlook for the core business and growth visibility? - Management expressed confidence in the core business's growth trajectory, with expectations for continued sequential growth across various segments [62][65] Question: Can you provide timing on the upcoming revenue step change in the data center? - Management noted that while there may be temporary bumps in the Copper Edge segment, overall data center growth is expected to continue [70] Question: How is the company approaching portfolio rationalization? - Management stated that they are patient in their approach to rationalization, focusing on strategic synergies rather than distressed sales [76] Question: What is the outlook for LoRa and its recent growth? - Management attributed the strong growth in LoRa to customer focus and new product development, with expectations for continued year-over-year growth [102][156]